Data / Form D filings / Immuno Cancer Biotherapeutics, Inc.
Immuno Cancer Biotherapeutics, Inc.: Form D filing
Immuno Cancer Biotherapeutics, Inc., a biotechnology company in Canton, SD, filed a Form D with the SEC in 2026. The latest, on October 15, 2026, reports $75,000 sold of an offering with no set size to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 48351 277TH ST, Canton, SD, 57013
- Phone
- (605) 310-7663
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2024
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2158173
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15 | New notice | Indefinite | $75,000 | 3 | Oct 9 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Robl | Executive Officer, Director | |
| Stephen Collins | Director |
Every Form D from the week of Oct 12 · All recent filings in South Dakota · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Immuno Cancer Biotherapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.